Swedish Agency Says EU ‘Studying’ Remdesivir

STOCKHOLM (AP) -
Empty vials of investigational coronavirus disease (COVID-19) treatment drug remdesivir are washed at a Gilead Sciences facility in La Verne, California. (Gilead Sciences Inc/Handout via Reuters)

The Swedish national drug and medicine supervision agency said that the European Union is investigating on a rapid schedule whether the use of the drug remdesivir could be allowed for treating the coronavirus within the 27-nation bloc following a similar decision in the United States.

The Swedish Medical Products Agency’s infection department director, Charlotta Bergqvist, told Swedish broadcaster TV4 that the introduction of remdesivir with is now being studied with a high priority within the EU and a decision may be reached “in a few days.”

The U.S. Food and Drug Administration recently authorized emergency use of remdesivir on people hospitalized with severe COVID-19. The drug was originally developed for treatment of Ebola and produced by the California-based Gilead Sciences Inc.

Clinical trials have showed the drug has helped to shorten the recovery time for people who were seriously ill.